Sagimet Biosciences' (SGMT) stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation ("BTD") to its lead pipeline candidate, denifanstat, for treating noncirrhotic metabolic dysfunction-associated steatohepatitis ("MASH"), a progressive and severe liver disease. The BTD is for treating MASH in patients who have moderate-to-advanced liver fibrosis (consistent with stage F2 and F3 disease). MASH is also called nonalcoholic steatohepatitis or NASH. The FDA grants ...